CoChat

Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition

Dresser, George K., Spence, J. David, Bailey, David G. · 2000 · Clinical Pharmacokinetics

The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.

Abstract

Drug interactions occur when the efficacy or toxicity of a medication is changed by administration of another substance. Pharmacokinetic interactions often occur as a result of a change in drug metabolism. Cytochrome P450 (CYP) 3A4 oxidises a broad spectrum of drugs by a number of metabolic processes. The location of CYP3A4 in the small bowel and liver permits an effect on both presystemic and systemic drug disposition. Some interactions with CYP3A4 inhibitors may also involve inhibition of P-glycoprotein. Clinically important CYP3A4 inhibitors include itraconazole, ketoconazole, clarithromycin, erythromycin, nefazodone, ritonavir and grapefruit juice. Torsades de pointes, a life-threatening ventricular arrhythmia associated with QT prolongation, can occur when these inhibitors are coadministered with terfenadine, astemizole, cisapride or pimozide. Rhabdomyolysis has been associated with the coadministration of some 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ('statins') and CYP3A4 inhibitors. Symptomatic hypotension may occur when CYP3A4 inhibitors are given with some dihydropyridine calcium antagonists, as well with the phosphodiesterase inhibitor sildenafil. Excessive sedation can result from concomitant administration of benzodiazepine (midazolam, triazolam, alprazolam or diazepam) or nonbenzodiazepine (zopiclone and buspirone) hypnosedatives with CYP3A4 inhibitors. Ataxia can occur with carbamazepine, and ergotism with ergotamine, following the addition of a CYP3A4 inhibitor. Beneficial drug interactions can occur. Administration of a CYP3A4 inhibitor with cyclosporin may allow reduction of the dosage and cost of the immunosuppressant. Certain HIV protease inhibitors, e.g. saquinavir, have low oral bioavailability that can be profoundly increased by the addition of ritonavir. The clinical importance of any drug interaction depends on factors that are drug-, patient- and administration-related. Generally, a doubling or more in plasma drug concentration has the potential for enhanced adverse or beneficial drug response. Less pronounced pharmacokinetic interactions may still be clinically important for drugs with a steep concentration-response relationship or narrow therapeutic index. In most cases, the extent of drug interaction varies markedly among individuals; this is likely to be dependent on interindividual differences in CYP3A4 tissue content, pre-existing medical conditions and, possibly, age. Interactions may occur under single dose conditions or only at steady state. The pharmacodynamic consequences may or may not closely follow pharmacokinetic changes. Drug interactions may be most apparent when patients are stabilised on the affected drug and the CYP3A4 inhibitor is then added to the regimen. Temporal relationships between the administration of the drug and CYP3A4 inhibitor may be important in determining the extent of the interaction.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003088-200038010-00003

Cites

167 of 167 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 167 references

Research works printed but not linked: 32

  1. Lown, 1994, Drug Metab Dispos, 22, 947
  2. Paintaud, 1996, Therapie, 51, 384
  3. Shimada, 1994, J Pharmacol Exp Ther, 270, 414
  4. Schinkel, 1998, Int J Clin Pharmacol Ther, 36, 9
  5. Wandel, 1999, Cancer Res, 59, 3944
  6. Edwards, 1996, Drug Metab Dispos, 24, 1287
  7. Schmiedlin-Ren, 1997, Drug Metab Dispos, 25, 1228
  8. Tsai, 1997, J Formos Med Assoc, 96, 144
  9. Gonzalez, 1998, Int J Clin Pharmacol Ther, 36, 292
  10. Baciewicz, 1993, Arch Intern Med, 153, 1970, 10.1001/archinte.1993.00410170042004 · doi:10.1001/archinte.1993.00410170042004
  11. Assan, 1994, Diabete Metab, 20, 49
  12. Corpier, 1988, JAMA, 260, 239, 10.1001/jama.1988.03410020105038 · doi:10.1001/jama.1988.03410020105038 · Paper page
  13. Lilja, 1999, Clin Pharmacol Ther, 66, 118, 10.1053/cp.1999.v66.100453001 · doi:10.1053/cp.1999.v66.100453001 · Paper page
  14. Donahue, 1999, Clin Pharmacol Ther, 65, 179
  15. Donahue, 1999, Clin Pharmacol Ther, 65, 179
  16. Vincent, 1999, Clin Pharmacol Ther, 61, 233
  17. Uno, 1999, Clin Pharmacol Ther, 61, 209
  18. Sigusch, 1994, Pharmazie, 49, 522
  19. Fuhr, 1998, Int J Clin Pharmacol Ther, 36, 126
  20. Bailey, 1992, Clin Pharmacol Ther, 51, 156
  21. von Moltke, 1996, J Pharmacol Exp Ther, 276, 370
  22. Yeates, 1996, Int J Clin Pharmacol Ther, 34, 400
  23. Olkkola, 1996, Anesth Analg, 82, 511
  24. Loiseau, 1985, Presse Med, 14, 162
  25. Berrettini, 1986, J Clin Psychiatry, 47, 147
  26. Pearson, 1990, J Clin Psychiatry, 51, 126
  27. Preskorn, 1997, Psychopharmacol Bull, 33, 659
  28. Hayton, 1969, N Z Med J, 69, 42
  29. Ioannides-Demos, 1997, J Rheumatol, 24, 49
  30. Gutmann, 1999, Mol Pharmacol, 56, 383, 10.1124/mol.56.2.383 · doi:10.1124/mol.56.2.383 · Paper page
  31. Kupferschmidt, 1998, Br J Clin Pharmacol, 45, 355, 10.1046/j.1365-2125.1998.t01-1-00687.x · doi:10.1046/j.1365-2125.1998.t01-1-00687.x · Paper page
  32. Furberg, 1996, Circulation, 93, 1475

Cited by

See all 921

Metadata

Authors
Dresser, G. K., Spence, J. D., & Bailey, D. G.
Affiliations
Western University (CA)
Corresponding author
Bailey, David G.
Venue
Clinical Pharmacokinetics
Published
2000-01
Volume
38
Issue
1
Pages
41-57
ISSN
0312-5963 (ISSN-L)
OpenAlex
W2005328285
Cited by
908
References
165
Citations by year
2026: 17 · 2025: 25 · 2024: 22 · 2023: 14 · 2022: 23 · 2021: 24 · 2020: 26 · 2019: 28 · 2018: 15 · 2017: 27 · 2016: 27 · 2015: 32 · 2014: 36 · 2013: 25 · 2012: 38
FWCI
6.22
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacokinetics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
CYP3A4 inhibitors, drug interactions, pharmacokinetic interactions, pharmacodynamic interactions, P-glycoprotein inhibition, torsades de pointes, QT prolongation, statin-induced rhabdomyolysis, benzodiazepine sedation, cyclosporine, HIV protease inhibitors, ritonavir, grapefruit juice
MeSH terms
Animals, Cytochrome P-450 Enzyme System, Drug Interactions, Drug Therapy, Enzyme Inhibitors, Humans, Mixed Function Oxygenases, Cytochrome P-450 CYP3A, Drug-Related Side Effects and Adverse Reactions, Cytochrome P-450 Enzyme Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition. https://app.cochat.ai/papers/10.2165/00003088-200038010-00003
The paper
Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000). Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-200038010-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.